Matches in SemOpenAlex for { <https://semopenalex.org/work/W4250769897> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4250769897 endingPage "6051" @default.
- W4250769897 startingPage "6051" @default.
- W4250769897 abstract "6051 Background: Patients with HD may require drug dose modification based on the severity of HD. HD is often assessed using CP criteria, the use of which is advocated by the FDA. CP criteria, originally developed for patients with end-stage liver disease, has 5 components -total bilirubin (TB), albumin, prothrombin time, ascites & encephalopathy. NCI-ODWG sponsored trials have used different criteria which utilize two objective and readily measurable laboratory parameters specifically - TB & aspartate aminotransferase (AST). Comparison of these 2 criteria has not been done previously. Methods: Forty-five patients with varying degrees of HD were enrolled in a Phase I clinical trial of imatinib mesylate. Data to assess CP score were collected prospectively, along with AST. Patients were stratified into 4 groups as per the NCI-ODWG criteria based on TB & AST: normal [TB & AST ≤ upper limit of normal (ULN)], mild HD (TB > ULN to 1.5 x ULN or AST > ULN), moderate HD (TB >1.5–3 x ULN, any AST) & severe HD (TB >3 - 10 x ULN, any AST). After calculating the CP score for each patient, the 2 criteria were compared. Results: Conclusions: When assessed with a composite index of TB & AST (NCI-ODWG criteria), normal-to-mild HD correlated with CP group A (where dose modification of chemotherapeutic agents is usually not necessary). Moderate-to-severe HD assessed by TB & AST correlated with CP groups B & C (where dose modification may be necessary). The NCI-ODWG index, using TB & AST, provides a simple & objective way of assessing HD & can be applied in outpatient clinics & clinical trials for dose modification of chemotherapy. In cancer patients, TB is the predominant factor in classifying the severity of HD . (Support: 1UO1-CA099168–01 & NIH/NCCR/GCRC #5M01 RR 00056) No significant financial relationships to disclose." @default.
- W4250769897 created "2022-05-12" @default.
- W4250769897 creator A5015643845 @default.
- W4250769897 creator A5021892503 @default.
- W4250769897 creator A5032059835 @default.
- W4250769897 creator A5033786876 @default.
- W4250769897 creator A5045286901 @default.
- W4250769897 creator A5052340302 @default.
- W4250769897 creator A5060442605 @default.
- W4250769897 creator A5080736692 @default.
- W4250769897 creator A5087941123 @default.
- W4250769897 creator A5090463921 @default.
- W4250769897 date "2004-07-15" @default.
- W4250769897 modified "2023-10-01" @default.
- W4250769897 title "Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): Implications for chemotherapy dosing" @default.
- W4250769897 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.6051" @default.
- W4250769897 hasPublicationYear "2004" @default.
- W4250769897 type Work @default.
- W4250769897 citedByCount "15" @default.
- W4250769897 countsByYear W42507698972013 @default.
- W4250769897 countsByYear W42507698972014 @default.
- W4250769897 countsByYear W42507698972015 @default.
- W4250769897 countsByYear W42507698972017 @default.
- W4250769897 countsByYear W42507698972018 @default.
- W4250769897 countsByYear W42507698972019 @default.
- W4250769897 countsByYear W42507698972021 @default.
- W4250769897 crossrefType "journal-article" @default.
- W4250769897 hasAuthorship W4250769897A5015643845 @default.
- W4250769897 hasAuthorship W4250769897A5021892503 @default.
- W4250769897 hasAuthorship W4250769897A5032059835 @default.
- W4250769897 hasAuthorship W4250769897A5033786876 @default.
- W4250769897 hasAuthorship W4250769897A5045286901 @default.
- W4250769897 hasAuthorship W4250769897A5052340302 @default.
- W4250769897 hasAuthorship W4250769897A5060442605 @default.
- W4250769897 hasAuthorship W4250769897A5080736692 @default.
- W4250769897 hasAuthorship W4250769897A5087941123 @default.
- W4250769897 hasAuthorship W4250769897A5090463921 @default.
- W4250769897 hasConcept C126322002 @default.
- W4250769897 hasConcept C141071460 @default.
- W4250769897 hasConcept C2777214474 @default.
- W4250769897 hasConcept C2777288759 @default.
- W4250769897 hasConcept C2777513400 @default.
- W4250769897 hasConcept C2780325230 @default.
- W4250769897 hasConcept C2780496750 @default.
- W4250769897 hasConcept C512861765 @default.
- W4250769897 hasConcept C71924100 @default.
- W4250769897 hasConcept C90924648 @default.
- W4250769897 hasConceptScore W4250769897C126322002 @default.
- W4250769897 hasConceptScore W4250769897C141071460 @default.
- W4250769897 hasConceptScore W4250769897C2777214474 @default.
- W4250769897 hasConceptScore W4250769897C2777288759 @default.
- W4250769897 hasConceptScore W4250769897C2777513400 @default.
- W4250769897 hasConceptScore W4250769897C2780325230 @default.
- W4250769897 hasConceptScore W4250769897C2780496750 @default.
- W4250769897 hasConceptScore W4250769897C512861765 @default.
- W4250769897 hasConceptScore W4250769897C71924100 @default.
- W4250769897 hasConceptScore W4250769897C90924648 @default.
- W4250769897 hasIssue "14_suppl" @default.
- W4250769897 hasLocation W42507698971 @default.
- W4250769897 hasOpenAccess W4250769897 @default.
- W4250769897 hasPrimaryLocation W42507698971 @default.
- W4250769897 hasRelatedWork W129680564 @default.
- W4250769897 hasRelatedWork W2094761667 @default.
- W4250769897 hasRelatedWork W2368152985 @default.
- W4250769897 hasRelatedWork W2379893296 @default.
- W4250769897 hasRelatedWork W2394144893 @default.
- W4250769897 hasRelatedWork W2466930327 @default.
- W4250769897 hasRelatedWork W2471036444 @default.
- W4250769897 hasRelatedWork W2744224482 @default.
- W4250769897 hasRelatedWork W3030708540 @default.
- W4250769897 hasRelatedWork W4293577549 @default.
- W4250769897 hasVolume "22" @default.
- W4250769897 isParatext "false" @default.
- W4250769897 isRetracted "false" @default.
- W4250769897 workType "article" @default.